Argenica Therapeutics (ASX:AGN) - Aandelenkoers, Nieuws & Analyse

AGN Overzicht aandelen

Argenica Therapeutics Limited, een biotechnologiebedrijf, houdt zich bezig met onderzoek naar en ontwikkeling van neuroprotectieve therapeutische geneesmiddelen in Australië.

Over het bedrijf

AGN fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

De winst is de afgelopen 5 jaar met 34% per jaar gedaald

Aandeelhouders zijn het afgelopen jaar verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( A$99M )

Heeft geen zinvolle omzet ( A$3M )

Argenica Therapeutics Limited Concurrenten

Recce Pharmaceuticals

ASX:RCE

AU$103.2m

Percheron Therapeutics

ASX:PER

AU$71.2m

Vitura Health

ASX:VIT

AU$56.4m

Vita Life Sciences

ASX:VLS

AU$118.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Argenica Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.77
52 Week Hoogtepunt	AU$0.98
52 Week Laag	AU$0.33
Bèta	0.79
11 maand verandering	11.59%
3 maanden verandering	-12.99%
1 Jaar Verandering	123.19%
33 jaar verandering	63.83%
5 jaar verandering	n/a
Verandering sinds IPO	196.15%

Recent nieuws en updates

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Sep 23

Recent updates

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Sep 23

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Jan 12

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Aug 12

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Apr 29

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Dec 30

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Sep 16

Rendement voor aandeelhouders

	AGN	AU Pharmaceuticals	AU Markt
7D	2.7%	-2.3%	-1.1%
1Y	123.2%	61.9%	16.1%

Rendement versus industrie: AGN overtrof de Australian Pharmaceuticals industrie, die het afgelopen jaar een rendement 61.9 % opleverde.

Rendement versus markt: AGN overtrof de Australian markt, die het afgelopen jaar een rendement opleverde van 16.1 %.

Prijsvolatiliteit

Is AGN's price volatile compared to industry and market?
AGN volatility
AGN Average Weekly Movement	7.8%
Pharmaceuticals Industry Average Movement	11.9%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.6%

Stabiele aandelenkoers: AGN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van AGN is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2019	n/a	Liz Dallimore	argenica.com.au

Argenica Therapeutics Limited, een biotechnologiebedrijf, houdt zich bezig met onderzoek naar en ontwikkeling van neuroprotectieve therapeutische geneesmiddelen in Australië. Haar belangrijkste productkandidaat is ARG-007, een neuroprotectieve peptidekandidaat, die zich in fase 2 van de klinische studie bevindt om de afsterven van hersenweefsel na een beroerte en andere soorten hersenletsel te verminderen. Argenica Therapeutics Limited werd opgericht in 2019 en heeft zijn hoofdkantoor in Nedlands, Australië.

Argenica Therapeutics Limited Samenvatting

Hoe verhouden de winst en inkomsten van Argenica Therapeutics zich tot de beurswaarde?
AGN fundamentele statistieken
Marktkapitalisatie	AU$98.63m
Inkomsten(TTM)	-AU$5.48m
Inkomsten(TTM)	AU$2.60m

38.0x

P/S-verhouding

-18.0x

Koers/Winstverhouding

Is AGN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AGN resultatenrekening (TTM)
Inkomsten	AU$2.60m
Kosten van inkomsten	AU$0
Brutowinst	AU$2.60m
Overige uitgaven	AU$8.08m
Inkomsten	-AU$5.48m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.043
Brutomarge	100.00%
Nettowinstmarge	-210.92%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde AGN op de lange termijn?

Bekijk historische prestaties en vergelijking

AGN Overzicht aandelen

Beloningen

Risicoanalyse

Argenica Therapeutics Limited Concurrenten

ASX:RCE

AU$103.2m

ASX:PER

AU$71.2m

ASX:VIT

AU$56.4m

ASX:VLS

AU$118.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Ms. Liddy Mccall Intends Not Stand for Re-Election as Non-Executive Director of Argenica Therapeutics Limited

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.

New major risk - Revenue and earnings growth

Recent updates

Ms. Liddy Mccall Intends Not Stand for Re-Election as Non-Executive Director of Argenica Therapeutics Limited

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics Limited Announces Preclinical Data Shows ARG-007 Inhibits A Cause of Alzheimers

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Approves Commencement of Fourth and Final Cohort Dosing

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics Limited Announces That the First Subjects in the Third Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Dosed

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee (SRC) to Progress to the Third Escalated Dose Cohort

Less than half of directors are independent

Argenica Therapeutics Limited Announces Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee to Progress to the Second Escalated Dose Cohort

Argenica Therapeutics Limited Announces Healthy Participants in the First Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Successfully Dosed, Indicating Good Safety and Tolerability of ARG-007 in These Participants

Argenica Therapeutics Limited Announces First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

Argenica Therapeutics Limited Announces Further Positive Preclinical Results for ARG-007 in Hypoxic-Ischaemic Encephalopathy

Argenica Therapeutics Limited, Annual General Meeting, Nov 24, 2022

Argenica Therapeutics Limited Announces Phase 1 Clinical Trial Summary

Argenica Therapeutics Limited Receives Ethics Approval to Commence Phase 1 Trial

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Argenica Therapeutics Limited Submits Application to Seek Approval to Commence Phase 1 Healthy Participant Study of ARG-007

Argenica Therapeutics Limited Appoints Dr. Jeffery Saver to Clinical Advisory Committee

Argenica Therapeutics Limited Announces Completion of the Final Pharmacokinetic (PK) Study of ARG-007 Required for the Phase 1 Clinical Trial

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Argenica Therapeutics Limited Announces Results of In-Life Rodent and Non-Human Primate Toxicology Studies Which Have Established the Maximum Tolerated Dose (MTD) of ARG-007

Less than half of directors are independent

Less than half of directors are independent

Argenica Therapeutics Limited Announces Management Changes

Argenica Therapeutics Limited Announces Positive Preclincal Data on Efficacy of ARG-007

Argenica Therapeutics Limited Announces Successful Completion of Final GLP Genotoxicity Studies

Argenica Therapeutics Announces Completion of Preliminary Pre-Clinical Tox Studies

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics Limited Provides Additional Information of Study Shows ARG-007 Does Not Degrade

Argenica Therapeutics Limited Provides Positive Preliminary for ARG-007

Argenica Therapeutics Limited Completes Pilot Pre-Clinical Pharmacokinetics Study

Argenica Therapeutics Limited has completed an IPO in the amount of AUD 7 million.

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Argenica Therapeutics Limited Samenvatting

38.0x

-18.0x

Inkomsten en omzet